Proton Radiotherapy for Recurrent Tumors

Retreatment of Recurrent Tumors Using Proton Therapy

The purpose of this study is to determine the feasibility of using proton radiotherapy for reirradiation of recurrent malignancies.

Study Overview

• Status: Completed
• Conditions: Tumors
• Intervention / Treatment: Other: Proton Radiotherapy

Detailed Description

Patients will be stratified by treatment site (Head and Neck, Thorax, Abdomen, Pelvis, Extremities) and by treatment volume (low volume, high volume) for a total of 10 strata. This study will be done in two phases. In the first phase, feasibility will be established using the primary objectives set below. The second phase will begin no earlier than 90 days after the last patient in the initial phase has completed treatment in each strata and once feasibility has been verified. The secondary objectives will serve as the objectives for the second phase of the study.

• Study Type: Interventional
• Enrollment (Anticipated): 24
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Illinois
    • Warrenville, Illinois, United States
      • ProCure Proton Therapy Center
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73142
      • Procure
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19104
      • Abamson Cancer Center of the University of Pennsylvania

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients with histologically confirmed, non-CNS solid malignancies who have been previously radiated and have a tumor recurrence in or near prior radiation fields. Re-biopsy of the recurrence is not required and left to the discretion of the treating physician, although every effort should be made to confirm recurrence.
• Patients must have a Karnofsky Performance Status of 60. Life expectancy of 3 months .
• Age greater or equal to 18.
• Patients must be able to provide informed consent.
• Women of child bearing potential as long as she agrees to use a recognized method of birth control (e.g. oral contraceptive, IUD, condoms or other barrier methods, etc.)
• Hysterectomy or menopause must be clinically documented.

Exclusion Criteria:

• Prior radiation treatment less than 3 months from planned start of re-irradiation of any part of the intended treatment volume.
• Pregnant women, women planning to become pregnant and women that are nursing.
• Actively being treated on any research study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: DIAGNOSTIC
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: small volume strata; 12 in small volume strata	Other: Proton Radiotherapy
ACTIVE_COMPARATOR: large volume strata; 12 in large volume strata	Other: Proton Radiotherapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Feasibility of proton therapy	To determine if the study is infeasible, defined if greater than 10% of pts experience one of the following: Patient cannot be given treatment because anatomy is such that a dosimetrically satisfactory treatment plan cannot be devised.; Patient who receives 15% or more of their treatments (for any reason, i.e. unable to set patient up within acceptable limits of tolerance, patient unable to tolerate treatment position or immobilization for duration of treatment) using photon radiotherapy (i.e. up to 15% of treatments could be delivered using photons).; Patient is unable to complete all of his/her treatments within 10 days of estimated date of treatment completion or requires a treatment break greater than 5 days.	90 days
Acute Toxicity	Acute Toxicity is defined as any grade 4 toxicity observed within 90 days from the initiation of radiotherapy that is felt to be directly related to their proton treatment. Toxicities will be graded by NCI CTC Version 4.0	within 90 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Late toxicity	Late toxicity is defined as any grade 3 or higher toxicity observed later than 90 days from start of therapy. Late toxicities will be graded according to the RTOG/EORTC late morbidity scoring system.	open-ended

Collaborators and Investigators

• Sponsor: Abramson Cancer Center of the University of Pennsylvania
• Investigators: Principal Investigator: Marcio Fagundes, MD, Procure, Oklahoma City, OK; Principal Investigator: William F. Hartsell, MD, ProCure Proton Therapy Center, Warrenville, IL

Study record dates

Study Major Dates

• Study Start (ACTUAL): February 1, 2010
• Primary Completion (ACTUAL): February 1, 2017
• Study Completion (ACTUAL): April 1, 2020

Study Registration Dates

• First Submitted: May 17, 2010
• First Submitted That Met QC Criteria: May 18, 2010
• First Posted (ESTIMATE): May 19, 2010

Study Record Updates

• Last Update Posted (ACTUAL): April 24, 2020
• Last Update Submitted That Met QC Criteria: April 23, 2020
• Last Verified: April 1, 2020

More Information

Terms related to this study

• Keywords: Adults with non-CNS recurrent tumors who have been previously irradiated; and have a tumor recurrence in or near prior radiation fields
• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Recurrence
• Other Study ID Numbers: UPCC 23309